Abstract
Antipsychotics are widely used for the treatment of behavioral and psychological symptoms of dementia (BPSD). Concerns have been raised in the literature over the safety of antipsychotics, with suggestions of an increased risk of mortality. The objective of this study was to determine the all-cause mortality risk associated with antipsychotic use among Alzheimer’s disease (AD) patients. A new-user study was conducted in a multicentric prospective cohort, composed of 534 community-dwelling mild-to-moderate AD patients recruited in 16 French memory centers. A survival analysis using a Cox proportional hazards model assessed hazard ratios (HRs) for death according to either first or second generation antipsychotic use (time-varying variable). Among the 534 patients, 102 new users were identified throughout the 3.5 year-follow-up period and 113 deaths occurred. The main antipsychotics used were risperidone and tiapride. Unadjusted and sociodemographic-adjusted (age, gender, center) analyses suggested an increased risk of death with antipsychotic use (HR: 1.84; 95% CI: [1.09-3.09] and HR: 1.93; 95% CI: [1.15-3.25]) respectively). However, antipsychotic use did not appear to be an independent predictive factor of death when dementia severity (cognitive status) was accounted for during fully adjusted multivariate analyses (HR: 1.12; 95% CI: [0.59-2.12]). Antipsychotic use may be associated with an increased risk of mortality, but to a lesser extent than several other factors which were found to be significant predictors of mortality (age, male gender, cognitive score, recent hospitalisation, medical aid). To date, antipsychotic risks outweigh their benefits in BPSD for which non-pharmacological approaches remain the first-line strategy and should be privileged.
Keywords: Antipsychotic agents, mortality, Alzheimer disease, dementia, cohort studies, antipsychotics, psychiatric disorders, neuroendocrine disease.
Current Alzheimer Research
Title:Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer’s Disease Patients: Evidence for a Role of Dementia Severity
Volume: 9 Issue: 9
Author(s): Virginie Gardette, Maryse Lapeyre-Mestre, Nicola Coley, Christelle Cantet, Jean-Louis Montastruc, Bruno Vellas and Sandrine Andrieu
Affiliation:
Keywords: Antipsychotic agents, mortality, Alzheimer disease, dementia, cohort studies, antipsychotics, psychiatric disorders, neuroendocrine disease.
Abstract: Antipsychotics are widely used for the treatment of behavioral and psychological symptoms of dementia (BPSD). Concerns have been raised in the literature over the safety of antipsychotics, with suggestions of an increased risk of mortality. The objective of this study was to determine the all-cause mortality risk associated with antipsychotic use among Alzheimer’s disease (AD) patients. A new-user study was conducted in a multicentric prospective cohort, composed of 534 community-dwelling mild-to-moderate AD patients recruited in 16 French memory centers. A survival analysis using a Cox proportional hazards model assessed hazard ratios (HRs) for death according to either first or second generation antipsychotic use (time-varying variable). Among the 534 patients, 102 new users were identified throughout the 3.5 year-follow-up period and 113 deaths occurred. The main antipsychotics used were risperidone and tiapride. Unadjusted and sociodemographic-adjusted (age, gender, center) analyses suggested an increased risk of death with antipsychotic use (HR: 1.84; 95% CI: [1.09-3.09] and HR: 1.93; 95% CI: [1.15-3.25]) respectively). However, antipsychotic use did not appear to be an independent predictive factor of death when dementia severity (cognitive status) was accounted for during fully adjusted multivariate analyses (HR: 1.12; 95% CI: [0.59-2.12]). Antipsychotic use may be associated with an increased risk of mortality, but to a lesser extent than several other factors which were found to be significant predictors of mortality (age, male gender, cognitive score, recent hospitalisation, medical aid). To date, antipsychotic risks outweigh their benefits in BPSD for which non-pharmacological approaches remain the first-line strategy and should be privileged.
Export Options
About this article
Cite this article as:
Gardette Virginie, Lapeyre-Mestre Maryse, Coley Nicola, Cantet Christelle, Montastruc Jean-Louis, Vellas Bruno and Andrieu Sandrine, Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer’s Disease Patients: Evidence for a Role of Dementia Severity, Current Alzheimer Research 2012; 9 (9) . https://dx.doi.org/10.2174/156720512803569037
DOI https://dx.doi.org/10.2174/156720512803569037 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoparticle-Encapsulated Bryostatin-1 Activates α-Secretase and PKC Isoforms In vitro and Facilitates Acquisition and Retention of Spatial Learning in an Alzheimer's Disease Mouse Model
Current Alzheimer Research Analytical Procedure for Determination of Cyclooxygenase-2 Inhibitors in Biological Fluids by High Performance Liquid Chromatography: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial: Early Recognition of Dementia in Primary Care- Current Issues and Concepts
Current Alzheimer Research Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Potential Phytotherapeutic Approaches for the Treatment of Alzheimer’s Disease: An Overview
Current Traditional Medicine Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews Mechanisms of Synaptic Homeostasis in Alzheimers Disease
Current Alzheimer Research VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina
Current Alzheimer Research Importance of Dietary Supplements to the Health
Current Nutrition & Food Science Assessing Depression in Patients with an Acute Coronary Syndrome: A Literature Review
Current Psychiatry Reviews From the Editors Perspective: Rational Approaches for Radical Entities
Current Neurovascular Research Present Status of Management of Mentally Ill Offenders in Japan: Critical Perspective from a Viewpoint of General Psychiatrist
Current Psychiatry Reviews Modulatory Effects of pH, Cu+2 and Sheet Breakers on Aggregation of Amyloid Peptides
Protein & Peptide Letters Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry Status Epilepticus: An Overview
Current Drug Metabolism Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Current Pharmaceutical Design Tau as a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design Molecular Dynamics Simulations of Intrinsically Disordered Proteins in Human Diseases
Current Computer-Aided Drug Design